BBI Life Sciences Corporation announced unaudited consolidated earnings results for the six months ended June 30, 2015. For the six months, the company reported revenue of RMB 131,780,000 against RMB 119,986,000 a year ago. Operating profit was RMB 26,051,000 against RMB 23,974,000 a year ago.

Profit before income tax was RMB 26,461,000 against RMB 53,195,000 a year ago. Total profit attributable to the shareholders was RMB 21,283,000 or RMB 0.039 diluted per share against RMB 40,682,000 or RMB 0.103 basic and diluted per share a year ago. Net cash generated from operating activities was RMB 3,475,000 against RMB 6,451,000 a year ago.

Purchase of property, plant and equipment was RMB 20,982,000 against RMB 4,858,000 a year ago. Purchase of intangible assets was RMB 1,834,000 against RMB 2,274,000 a year ago. Revenue representing an increase of 9.8% from the same period of 2014, this is mainly contributed by the steady growth of the Four Business Segments.

After deducting non-recurring one-off gain for the same period of 2014 (the gain on the disposal of 31% equity interest in Shanghai PrimeGene Bio-Tech Co. Ltd.), the adjusted net profit was approximately RMB 21.21 million, representing an increase of 0.3%.